PFE · NYSE
Consensus is $0.84 EPS for Sep 2026 across 6 estimates, ranging $0.71 to $0.94.
No consensus figures are on file, so the quarter cannot be judged against an external earnings estimate. Revenue was $15.034 billion, up from $14.653 billion a year earlier, with Biopharma carrying the business at $14.661 billion versus $14.305 billion. However, Biopharma earnings were essentially flat at $6.887 billion versus $6.891 billion, as cost of sales increased to $3.188 billion from $3.075 billion and research and development expense rose to $2.376 billion from $2.109 billion. Primary Care revenue edged down to $5.503 billion from $5.535 billion, although Eliquis, Nurtec ODT/Vydura and Abrysvo grew. COVID products dragged on the mix: Paxlovid revenue dropped to $21 million from $427 million and Comirnaty to $261 million from $381 million. Total earnings swung to a $653 million loss from $3.044 billion of earnings, primarily because of $4.3 billion in asset impairments and $842 million in legal charges.
No forward guidance was given in the supplied material. The filing provides quarterly and six-month historical revenue, segment earnings, product revenue and geographic revenue, but no ranges for revenue, earnings, margins, operating expenses, cash flow or capital expenditures. It therefore does not provide a new guide to compare with a prior guide, nor does it state assumptions or caveats for the periods ahead. Management's discussion of the revised Biopharma and PC1 operating structure describes how the company is organized, not a forecast for future performance.
